State of Nevada
Department of Health and Human Services

Diabetic Supply
Educational Webinar
Division of Health Care Financing & Policy

Holly Long, SSPS III

March 24, 2020

Helping people. It’s who we are and what we do.
Agenda

Policy & PA Overview
- Holly Long, MS, SSPS III, DHCFP

Omnipod®
- Michelle Tori, RD, CDCES, ADEPT Certified Medicaid Account Manager, Omnipod®

Dexcom G6®
- Carrie Sinnott, Regional Account Executive, Dexcom®

FreeStyle Libre 14 Day®
- Peter Johns, Regional Sales Director, Abbott Diabetes Care
Policy & PA Overview

• FFS only – does not apply to recipients enrolled in an MCO
• Preferred Diabetic Products: Omnipod, Dexcom G6 and FreeStyle Libre 14 Day
  • Includes tubeless insulin delivery system and CGM receivers and readers
  • Requires clinical PA for approval - Requires a diagnosis of DM1
• Preferred Diabetic Supplies
  • Includes sensors and transmitters
  • Does NOT require a PA - Requires a diagnosis of DM1
Michelle Tori, RD, CDCES, ADEPT Certified Medicaid Account Manager - West

Insulet Corporation
## Insulet Corporation

### About Insulet

<table>
<thead>
<tr>
<th><strong>1,000+ employees</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direct operations</strong></td>
</tr>
<tr>
<td>US, Canada and Europe</td>
</tr>
<tr>
<td><strong>Innovation Focus</strong></td>
</tr>
<tr>
<td>• Forbes 2017 - #4 on “Most Innovative Growth Companies”</td>
</tr>
<tr>
<td>• Innovation Technology Center in California</td>
</tr>
</tbody>
</table>

### Manufacturing in the US

- Plan to produce 3 million Pods from Acton, MA facility by the end of 2020
  - Made in USA product for our USA customers
  - Hired over 70 manufacturing jobs in USA

### NEW Omnipod DASH™ System
The Power of Pod Therapy

Simple. Smart. Discreet

- Tubeless, Waterproof, Pod*
- Remote Bolus Delivery for Convenience
- No Need to Disconnect

- Automatic Cannula Insertion
- Site Rotation Tracker
- Convenient Pharmacy Access

*The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.
Intuitive and Simple to Use Color Touchscreen

- User-centric and modern design
- Secure, locked down smartphone
- Bluetooth® Wireless Technology
- Integrated CalorieKing® food library
- Zero basal rate
- Fractional IC Ratios

Omnipod DASH™ System PDM
Easy to Use and Teach

1. Fill Pod with Insulin
2. Pair PDM and Pod
3. Apply Pod
Integrated CalorieKing®* Food Library

Ability to search for specific food items

Access to over 80,000 branded and unbranded foods

Can set frequently eaten foods as favorites

Can create series of customized meals

Simplifies carb counting

*Available in the English language only
Fine-Tuned Insulin Delivery

- Zero Basal
- Fractional I:C Ratios
- Site map tracks Pod changes & encourages site rotation
Access to Insulin Delivery via Mobile Apps—Now Available!

**Omnipod DISPLAY™ App**

Secondary PDM display on personal smartphone*

**Omnipod VIEW™ App**

12 caregivers can view Pod info on personal smartphone *

**Today View Widget**

CGM and Pod single screen view on iOS devices**

---

*The following iOS 11.3 compatible smartphone devices are available for use with the Omnipod VIEW™ App: iPhone 5S, 6, 6 Plus, 6S, 6S Plus, 5SE, 7, 7 Plus, 8, 8 Plus, and iPhone X. Available with DASH™ PDM version 1.0.50 and above.

**The Dexcom System does not have integrated functionality with the Omnipod DASH™ System. iPhone widgets are mobile application shortcuts that are visible after swiping right from the home screen to the iPhone’s Today View**
Insulet Provided Glooko

- Allows upload in or outside of clinic
- Overlays data from Omnipod DASH™ System, CGMs, BG meters, and fitness devices
- Multiple reports: Summary, AGP, Calendar View, Logbook, Daily Summary, and Device Settings
- Enables population tracking
13
BENEFIT: Improved Quality of Life

Percentage of Patients Reporting Improved QoL

Survey of more than 1,200 Adults with Type 1 Diabetes Demonstrates Improved Quality of Life

66% of Podders™ would not be using a pump if not for the Omnipod® System®

Pod Therapy
The Easiest to Use Insulin Delivery System*

93%**
Of Podders™ said that insulin delivery is easier with the Omnipod® System**

97%**
Of Podders™ would recommend the Omnipod® System to a friend**

*Argent Study. The methodology analyzed the User Guides for several commercially available self-managed insulin delivery systems, including insulin Omnipod® System, Yancey 2 InterM, Medtronic, Minimed®, and Medtronic® Eros®. **This survey was completed on a prior generation of the Omnipod® Insulin Management System. Data on file.
Risk Statement

Important Safety Information: The Omnipod DASH™ Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. Additionally, the Omnipod DASH™ System is interoperable with a compatible blood glucose meter to receive and display blood glucose measurements. The Omnipod DASH™ System has been tested and found to be safe for use with the following U-100 insulin: Novolog®, Humalog®, Apidra®, Admelog® or Fiasp®. Refer to the Omnipod DASH™ Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.
Transforming Diabetes Management By Advancing CGM Technology

CGM = continuous glucose monitoring.
Intended For Payer Audience Only

dexcomG6

Smart devices sold separately.
BGM or Intermittent Scan Monitoring Is Not Enough

Dexcom’s real-time CGM can automatically alert a patient to take necessary action¹

**Target Glucose Range**

- The American Diabetes Association (ADA) differentiates RT-CGM from IS-CGM.² All individuals with increased risk for hypoglycemia should consider RT-CGM over IS-CGM³
- The Endocrine Society excludes IS-CGM from its recommendations, noting that it does not offer “true CGM” in terms of providing alerts for high and low blood glucose levels⁴

BGM = blood glucose monitoring; CGM = continuous glucose monitoring; IS-CGM = intermittent scan continuous glucose monitoring; RT-CGM = real-time continuous glucose monitoring.

The Unique Features of Dexcom G6 Improve Diabetes Management

- Robust clinical evidence of improved glycemic outcomes
- Exceptional accuracy
- Class II device designation
- Zero fingersticks required
- Up to 288 continuous readings per day
- Customizable alerts and a fixed Urgent Low alarm
- Predictive Urgent Low Soon alert
- Data share features with up to 10 followers

Studies prove the clinical benefits of the differentiating attributes of Dexcom.

*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
†Separate Follow app required.
CGM = continuous glucose monitoring.


Intended For Payer Audience Only
Dexcom G6 System

Approved March 27, 2018 for ages 2 years and older

**G6 Sensor**
- Factory calibrated
- Acetaminophen Blocking
- Improved accuracy
- 10 day sensor

**G6 Auto Applicator**
- Simple, one-handed application

**G6 Transmitter**
- 30% reduction in overall size

**G6 Display Device**
- Touch screen receiver
- Urgent low soon alert
- Android/iOS smart devices and wearables
Easy to Insert: Peel-Press-Push-Place

Clinical Study Results

- 100% of all subjects rated the new applicator system as “very easy” or “somewhat easy”
- 84% rated the system as “painless”
- 100% of all subjects rated the instructions for sensor insertion to be “somewhat or very easy”
Dexcom’s predictive alert *warns users of impending hypoglycemia*.¹

<table>
<thead>
<tr>
<th>Infrequent screen viewers</th>
<th>Frequent screen viewers</th>
</tr>
</thead>
<tbody>
<tr>
<td>(&lt; 3.30 views per day)</td>
<td>(&gt; 8.25 views per day)</td>
</tr>
<tr>
<td><strong>36% reduction</strong> in time spent in hypoglycemia &lt; 70 mg/dL</td>
<td><strong>Nearly 50% reduction</strong> in time spent in hypoglycemia &lt; 70 mg/dL</td>
</tr>
</tbody>
</table>

93% of G6 users enabled the Urgent Low Soon alert.²

*The Puhr et al study examined 15,000 patients who used Dexcom G6 and its mobile app for at least 30 days with or without the Urgent Low Soon alert enabled. The Urgent Low Soon alert forecasts when glucose will be ≤ 55 mg/dL within 20 minutes. Patients who infrequently viewed the screen but had the alert enabled reduced their time spent in hypoglycemia by more than 36% compared to those with the Urgent Low Soon alert disabled. Frequent screen viewers reduced their time spent in hypoglycemia by nearly 50%.²*


Intended For Payer Audience Only
Dexcom G6 allows for remote monitoring of the patient’s glucose data, increasing their circle of support.
Dexcom CLARITY is a cloud-based diabetes management software that helps patients and providers understand and analyze glucose patterns.¹

Home user¹:
- View glucose patterns, trends, and statistics with the Dexcom CLARITY app
- Get weekly notifications to know how much time is spent in target range
- Regular push notifications facilitate coaching and decision support

HCP²:
- Data can be shared with HCPs on an ongoing basis to make appointments more efficient
- Data available on demand
- No downloading required saves valuable time
- Graphs show patterns of hypoglycemia and hyperglycemia, allowing providers to prioritize problems and find diabetes management solutions

Being able to easily analyze glucose patterns helps patients and providers find diabetes management solutions.³

---

CGM = continuous glucose monitoring; HCP = healthcare provider.

Intended For Payer Audience Only
# How to Order Dexcom G6 at the Pharmacy

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>QUANTITY</th>
<th>REFILLS</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXCOM G6 RECEIVER KIT</td>
<td>1-PACK</td>
<td>ONCE A YEAR</td>
<td>08627-0091-11</td>
</tr>
<tr>
<td>DEXCOM G6 TRANSMITTER KIT</td>
<td>1-PACK</td>
<td>EVERY 3 MONTHS</td>
<td>08627-0016-01</td>
</tr>
<tr>
<td>DEXCOM G6 SENSOR KIT</td>
<td>3-PACK</td>
<td>EVERY 30 DAYS</td>
<td>08627-0053-03</td>
</tr>
</tbody>
</table>
**Pharmacy Prior-Authorization**

**Nevada Medicaid**
Submit fax request to: 855-455-3303
Please note: All information below is required to process this request.

**Continuous Glucose Monitors (CGMs) Prior Authorization Request Form**

<table>
<thead>
<tr>
<th>Member Information (required)</th>
<th>Provider Information (required)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Name:</td>
<td>Provider Name:</td>
</tr>
<tr>
<td>Insurance ID#:</td>
<td>NPI#:</td>
</tr>
<tr>
<td>Date of Birth:</td>
<td>Specialty:</td>
</tr>
<tr>
<td>Street Address:</td>
<td>Office Phone:</td>
</tr>
<tr>
<td>City:</td>
<td>Office Fax:</td>
</tr>
<tr>
<td>State:</td>
<td>Office Street Address:</td>
</tr>
<tr>
<td>Zip:</td>
<td>City:</td>
</tr>
<tr>
<td>Phone:</td>
<td>State:</td>
</tr>
</tbody>
</table>

**Device Information** (required)

- Device Name:
- Additional Information:

**Clinical Information** (required)

- Mark all that apply:
  - The recipient has a diagnosis of Diabetes Mellitus Type I or Gestational Diabetes. ICD-10: C11
  - The product requested is approved for the age of the recipient per the manufacturer’s label.
  - The recipient has been compliant on their current antidiabetic regimen for at least the last six months (requiring at least three injections per day).
  - The recipient has a documented history of recurring hypoglycemia.
  - The recipient has wide fluctuations in pre-meal blood glucose, history of severe glycemic excursion or experiencing “Dawn” phenomenon with fasting blood glucose exceeding 200mg/dL.
  - The recipient is currently using insulin pump therapy while continuing to need frequent dosage adjustments or experiencing recurring episodes of severe hypoglycemia (50 mg/dL).

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

---

- Prescriber completes Optumx Rx Prior Authorization form
- Once authorized, please send prescription to pharmacy

[https://www.medicaid.nv.gov/providers/rx/rxforms.aspx](https://www.medicaid.nv.gov/providers/rx/rxforms.aspx)
Dexcom Support and Services

See what’s in the box.
Find your illustrated Dexcom G6 Start Here guide and Using Your Dexcom G6 guide.

Watch online tutorials.
dexcom.com/tutorials

Watch training videos.
dexcom.com/training-videos

Talk to the experts.

Technical Support
Available 24/7 for questions about product troubleshooting. 844-607-8398

Dexcom CARE®
Provides CGM training and guidance from a team of certified diabetes educators. 888-738-3646

Customer Sales Support
Assists with Dexcom orders. 888-738-3646
Provider and Pharmacy Resources

• **Local Support:**

  Gretchen Anderson: NV Territory Business Manager  
  702-569-5855  
  gretchen.anderson@dexcom.com

• **HCP and Pharmacy Education:**

  Visit our website: [www.provider.dexcom.com](http://www.provider.dexcom.com)
Safety Statement

BRIEF SAFETY STATEMENT

Indications for Use: The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real-time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older.

The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 System results should be based on the glucose trends and several sequential readings over time. The Dexcom G6 System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments.

The Dexcom G6 System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The Dexcom G6 System can be used alone or in conjunction with these digitally connected medical devices for the purpose of managing diabetes.

Contraindication: Don’t wear your CGM (sensor, transmitter, receiver, or smart device) for magnetic resonance imaging (MRI), computed tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. The G6 hasn’t been tested in those situations. The magnetic fields and heat could damage the components of the G6, which may cause it to display inaccurate G6 sensor glucose readings (G6 readings) or may prevent alerts. Without G6 readings or alarm/alert notifications, you might miss a severe low or high glucose event.
Safety Statement

BRIEF SAFETY STATEMENT (CONT’D)

Warnings:

Read User Materials
Before you use your G6, carefully read the materials included with it. If you don’t, you might:

• Not use the G6 correctly
• Not understand G6 information
• Affect how well it works

Don't Ignore Low/High Symptoms
Don't ignore how you feel. If your glucose alerts and readings don't match what you're feeling, use your blood glucose meter (meter) to make diabetes treatment decisions or, if needed, seek immediate medical attention. When in doubt, get your meter out.

No Number, No Arrow, No CGM Treatment Decision
If your G6 doesn’t show a number or arrow, or your readings don’t match your symptoms, use your meter to make diabetes treatment decisions. No number, no arrow, no treatment decision. When in doubt, get your meter out.

Don't Use If...
Do not use the G6 if you are pregnant, on dialysis, or critically ill. It is not known how different conditions or medications common to these populations may affect performance of the system. G6 readings may be inaccurate in these populations.

Follow G6 instructions. If you don’t, you could have a severe low or high glucose event.

© 2019 Dexcom, Inc. All rights reserved. This product is covered by U.S. patent.
Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
Thank you!
The FreeStyle Libre 14 Day System Overview
Indications and Important Safety Information

FreeStyle Libre 14 day Flash Glucose Monitoring system is a continuous glucose monitoring (CGM) device indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The system is intended for single patient use and requires a prescription.

CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The systems do not have alarms unless the sensor is scanned, and the systems contain small parts that may be dangerous if swallowed. The systems are not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.
Features and Benefits
FreeStyle Libre 14 day System is a simple and accurate CGM for patients\(^1\)

**2 out of 3 people with diabetes do not comply with blood glucose monitoring as prescribed\(^2\)**

**FreeStyle Libre 14 day System provides a more complete glucose picture, helping patients make better treatment decisions**\(^*\)

---

1. FreeStyle Libre 14 day System User’s Manual

\(^*\) Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
FreeStyle Libre 14 day sensor is factory-calibrated CGM sensor to eliminate fingersticks for calibration

- Small, discreet, and easy for patients
- Worn up to 14 days on back of upper arm
  Scan to activate and wait 1 hour for first glucose reading
- Very thin filament
  Filament is <0.4mm thick and inserted 5mm beneath the skin to measure interstitial fluid
- Water-resistant
  Exercise, shower, and swim in a depth of up to 1 meter for 30 minutes
- Automatically measures glucose readings day and night
  Continuously measures glucose every minute and records readings every 15 minutes. Stores up to 8 hours of glucose data

2. Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes
3. Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours
FreeStyle Libre 14 day reader provides simple yet comprehensive data for better diabetes management\(^1\)

- **Real-time glucose readings with painless\(^2\) scan**  
  Provides insightful glucose trend arrows and history
- **An easy scan shows the latest 8 hours of glucose history**  
  Captures data from sensor when it is within 1- 4 cm of the sensor

FreeStyle LibreLink app provides easy access to glucose insights on compatible mobile devices*

Compatible
Free to download and compatible with and FreeStyle Libre 14 day sensors¹,²

User-friendly
Shows current glucose readings, trend arrow, trends and patterns on iPhone or Android*

Seamless
Automatically uploads glucose data to the patient’s LibreView account³ and allows sharing of reports from the app

*The FreeStyle LibreLink app is compatible with NFC-enabled smartphones running Android OS 5.0 or higher and iPhone 7 or later running iOS 11 or later.
1. FreeStyle LibreLink app and the FreeStyle Libre 14 day readers have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose
2. FreeStyle Libre 14 day sensor communicates with the FreeStyle Libre 14 day reader or the FreeStyle LibreLink app that started it. However, if the sensor is started with the app first, the reader cannot be used during the remainder of the sensor wear period.
3. Patients require a LibreView, a service provided by Abbott and Newyu, inc, account to use FreeStyle LibreLink
FreeStyle Libre 14 day System allows patients to monitor and respond to changing glucose levels.
FreeStyle Libre 14 day System is easy for people with diabetes to use

1 Easy to start
- Apply the sensor to back of the upper arm
- Sensor is worn for 14 days

2 Easy to scan
- Obtain real-time glucose readings with painless scan
- Each scan provides current glucose reading, 8 hour glucose history, and glucose trend arrow

3 Easy to review
- Review glucose readings and history on reader
- Glucose readings can be uploaded and viewed and shared on LibreView

LibreView is developed, distributed, and supported by NewYu, Inc. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice. Trademarks are the property of their respective owners.

Accuracy
CGM reinvented for accuracy\textsuperscript{1} without daily calibration

- The first personal CGM able to maintain accuracy\textsuperscript{1} over 14 days without the need for fingerstick calibration or sensor coding\textsuperscript{*}

- Factory calibration delivers clinically proven accuracy\textsuperscript{1}

- FreeStyle Libre 14 day system achieved a MARD of 9.4\% over 14 days\textsuperscript{1}

\textsuperscript{1. FreeStyle Libre 14 day System User's manual}
\textsuperscript{* Calibration or coding not required by the user}
Clinically proven to be accurate\textsuperscript{1}, stable and consistent over 14 days without the need for fingerstick calibration

Abbott’s CGM technology reinvents accuracy\textsuperscript{1} without need for daily calibration:

\begin{itemize}
  \item Factory calibration eliminates patient calibration errors
  \item Wired enzyme technology ensures stable sensor performance\textsuperscript{2}
\end{itemize}

\textbf{9.4\% average MARD* over 14 days}

\begin{itemize}
  \item Day 1: 10.8\%
  \item Day 6: 8.5\%
  \item Day 11: 9.3\%
  \item Day 14: 9.1\%
\end{itemize}

\textsuperscript{1} FreeStyle Libre 14 day System User’s Manual

\* MARD (mean absolute relative difference) is compared to reference YSI (Yellow Springs Instrument) values
FreeStyle Libre 14 day System delivers proven accuracy\textsuperscript{1}

High degree of agreement between sensor readings and YSI values\textsuperscript{2}

\textbf{89.5\%} of glucose results within Zone A

\textbf{100\%} of glucose results within Zones A \& B

- **Zone A**: No effect on clinical action (considered clinically accuracy)
- **Zone B**: Altered clinical action, but no or little effect on clinical outcome
- **Zone C**: Altered clinical action – likely to affect clinical outcome
- **Zone D**: Altered clinical action – could have significant medical risk
- **Zone E**: Altered clinical action – could have dangerous consequences

\textsuperscript{1} FreeStyle Libre 14 day System User’s manual
\textsuperscript{2} Data on file. Abbott Diabetes Care

FreeStyle, Libre, and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions. © 2020 Abbott. ADC-10090 v2.0 03/20

Proprietary and confidential — do not distribute
Clinical, Real-World Data, and Meta-analysis
In clinical trials, FreeStyle Libre 14 day System led to more frequent glucose monitoring.

1. Bolinder et al., The Lancet 388.10057 (2016): 2254-2263. Data from this study is collected from FreeStyle Libre System.
2. Haak et al., Diabetes Therapy 8.1 (2017): 55-73. Data from this study is collected from FreeStyle Libre System.
FreeStyle Libre 14 day System reduced time in hypoglycemia and hypoglycemia episodes

Nocturnal hypoglycemia
<70 mg/dL

Serious hypoglycemia
<55 mg/dL

Hypoglycemia episodes

T1D Patients
(IMPACT)¹

T2D Patients
(REPLACE)²

26%

1. Bolinder et al., The Lancet 388(10057) (2016): 2254-2263. Data from this study is collected from FreeStyle Libre System.
2. Haak et al., Diabetes Therapy 8.1 (2017): 55-73. Data from this study is collected from FreeStyle Libre System.
FreeStyle Libre 14 day System demonstrated similar outcomes in real world data\(^1\)

\[ \text{>680,000 readers}\]  
\[8.5B\] glucose measurements  
\[\text{>4}\] years of data

FreeStyle Libre 14 day System users check glucose frequently\(^1\)  
12 average scans per day

In meta-analysis, FreeStyle Libre 14 day System showed greater HbA1c* reduction with higher initial HbA1c*1

29 STUDIES
1723 PARTICIPANTS

A meta-analysis of clinical and real world observational studies among type 1 and type 2 people with diabetes was conducted to assess the impact of using the FreeStyle Libre 14 day System on HbA1c

HbA1c reduction was observed in the first 2 months and sustained over a 12-month period


* Average HbA1c

FreeStyle, Libre, and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions. © 2020 Abbott. ADC-10090 v2.0 03/20
PATIENTS CAN DO IT
WITHOUT FINGERSTICKS*

*Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
Preferred Product Information

- Omnipod Dash® 5, please contact (800) 591-3455, Option 2 and visit https://www.myomnipod.com/DASH

- Dexcom G6® products, please contact (702) 569-5855 and visit https://provider.dexcom.com

- FreeStyle Libre® Reader and Sensor, please contact (855) 632-8658 and visit https://www.freestylelibre.us/system-overview/freestyle-14-day.html
DHCFP Contacts & Resources

Holly M. Long, MS, SSPSS III, DHCFP, hlong@dhcfp.nv.gov

Pharmacy Inquiries: rxinfo@dhcfp.nv.gov

Diabetic Supply Program Web Site:
https://www.medicaid.nv.gov/providers/rx/diabeticsupplies.aspx

MSM Chapter 1200 Policy:
http://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C1200/Chapter1200/

PA Forms: https://www.medicaid.nv.gov/providers/rx/rxforms.aspx